Portal de Periódicos da CAPES

Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals

2017; Elsevier BV; Volume: 89; Issue: 1 Linguagem: Inglês

10.1016/j.diagmicrobio.2017.06.006

1879-0070

Juan Carlos Alados, Inmaculada Pavón Guerrero, María José Blanco Rodríguez, Eva Torres Martos, Ana Belén Pérez, Cristina Leon, Jesus F. Sierra Sánchez, María Dolores López Prieto, Natalia Chueca Porcuna, María Dolores Ocete Mochón, Juan Macı́as, Alberto de la Iglesia, Javier Rodríguez Granger, Marcial Delgado Fernández, Inmaculada Lozano, Elena Reigadas, Antonio Rivero, María del Carmen Lozano Domínguez, Isabel Viciana, Juan Carlos Galán Montemayor, Féderico García,

HIV/AIDS drug development and treatment

We evaluated the utility of Architect core antigen assay® Abbott Diagnostics (HCVAg) for monitoring patients with HCV infection and compared to HCV-RNA quantification (Cobas Ampliprep TaqMan-Roche Diagnostics). Samples from 262 patients were studied. Mean baseline HCV RNA and HCVAg levels were similar for responders (6.2 log IU/mL and 3.4 log fmol/L) and non-responders (6.1 log IU/mL and 3.2 log fmol/L), respectively. Only 10 patients failed to achieve SVR12 and all were detected by both assays. To evaluate HCVAg quantification as a tool for the detection of failure to DAAs, we performed a retrospective study of 132 non-responder patients. Mean HCV RNA and HCVAg levels at the time of detection of therapeutic failure were 5.88±0.97 log IU/mL and 3.19±0.79 log fmol/L, respectively. HCVAg (>3 fmol/L) was detected in 130/132 patients (98.5%). HCVAg assay was useful for patient selection and for evaluating virological response to DAAs in the real world.